B6E.SG - Swedish Orphan Biovitrum AB
| Previous Close | 18.02 |
| Open | 18.56 |
| Bid | 18.12 x 100000 |
| Ask | 19.16 x 100000 |
| Day's Range | 18.56 - 18.56 |
| 52 Week Range | 18.01 - 23.82 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ZacksIs Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
Here is how Alcon (ALC) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
ZacksIs ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
Here is how Adma Biologics (ADMA) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
Motley FoolWhy Shares of CTI BioPharma Are Soaring Wednesday
What happened Shares of CTI BioPharma (NASDAQ: CTIC) were up more than 80% early Wednesday after the company announced it was getting bought out for $1.7 billion by Swedish Orphan Biovitrum AB (OTC: BIOVF), also known as SOBI.
BloombergSweden’s Sobi to Buy CTI Biopharma for $1.7 Billion
(Bloomberg) -- Swedish Orphan Biovitrum AB agreed to buy US biotech CTI BioPharma Corp., which develops therapies for blood-related cancers, in a deal valued at $1.7 billion.Most Read from BloombergSteve Schwarzman Holds Off Giving Money to DeSantis After Meeting HimItaly Intends to Exit China Belt and Road Pact as Ties SourUS Inflation Shows Signs of Moderating, Giving Fed Room to PauseVanguard’s Trillion-Dollar Man Leads a Fixed-Income RevolutionTrump Liable for Sex Abuse, Must Pay $5 Million
- Reuters
Sweden's SOBI offers $1.7 billion to buy CTI BioPharma
Drugmaker Swedish Orphan Biovitrum (SOBI) said on Wednesday it had agreed to make a $1.7 billion cash offer for CTI BioPharma, a U.S. biopharmaceutical company focused on blood related cancers and rare diseases. SOBI said it would make a tender offer for $9.10 per CTI share, a premium of 89% over Tuesday's closing price of $4.82, to be partly funded via a share issue, sending CTI's stock sharply higher in early U.S. trade. The acquisition is aimed at expanding SOBI's rare haematology franchise, the company's CEO Guido Oelkers said in an interview.
- Reuters
UPDATE 3-Sweden's SOBI makes $1.7 bln offer to buy CTI BioPharma
Drug maker Swedish Orphan Biovitrum (SOBI) said on Wednesday it had agreed to make a $1.7 billion cash offer to buy CTI BioPharma, a U.S. biopharmaceutical company focused on blood related cancers and rare diseases. SOBI, a rare disease drugmaker, said it would make a tender offer for $9.10 per CTI share, a premium of 89% over Tuesday's closing price of $4.82, to be partly funded via a share issue.
ZacksSwedish Orphan Biovitrum (BIOVF) Q1 Earnings and Revenues Beat Estimates
Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 54.55% and 5.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksAstraZeneca (AZN), Sanofi Simply RSV Antibody Agreement Terms
AstraZeneca (AZN) and Sanofi (SNY) revise the contractual terms of the agreement for Beyfortus. Sanofi will have full commercial control of Beyfortus in the United States.
GlobeNewswireAnnals of Rheumatic Diseases Publishes Results from Phase 2 Study of emapalumab in Patients with Secondary HLH/Macrophage Activation Syndrome
Results showed that MAS remission was seen in 13 of 14 patients with sHLH/MAS receiving emapalumab who had an inadequate response to high-dose glucocorticosteroidsWALTHAM, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), today announced that the Annals of Rheumatic Diseases has published results from an open-label, single-arm, multicenter phase 2 study evaluating the safety and efficacy of emapalumab, an
ZacksApellis' (APLS) Earnings Top, Empaveli Sales Boost Revenues
Apellis Pharmaceuticals (APLS) reports better-than-expected results, beating both earnings and revenue estimates. Empaveli sales continue to boost product revenues for the company.
GlobeNewswireSobi Receives Approval from Health Canada for Empaveli™ (pegcetacoplan) for the Treatment of Certain Patients with Paroxysmal Nocturnal Hemoglobinuria
The first targeted C3 therapy approved in CanadaApproval based on results from head-to-head PEGASUS phase 3 study where Empaveli™ demonstrated superiority to eculizumab in improving hemoglobin levels1On trial, transfusion avoidance was achieved by 85.4% patients in the Empaveli group versus 15.4% in the eculizumab group1 WALTHAM, Mass., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), announced today that Health
- Reuters
UPDATE 2-U.S. authorizes Sobi's drug to treat COVID-19 in high-risk patients
Sobi North America, a unit of Swedish Orphan Biovitrum AB, said on Thursday the U.S. Food and Drug Administration authorized its arthritis drug for treatment of high-risk hospitalized COVID-19 patients. The drug, already approved in the European Union for treating COVID, has been authorized in the United States to treat patients with pneumonia who require oxygen support and those at risk of developing severe respiratory failure. The authorization of Sobi's Kineret adds another option for COVID treatment in the United States, as the disease moves from a pandemic to an endemic stage.
- GlobeNewswire
U.S. Food and Drug Administration Issues Emergency Use Authorization for KINERET® (anakinra) for the Treatment of COVID-19-Related Pneumonia
Early treatment with KINERET reduced disease progression by 64 percent in hospitalized COVID-19 patientsi WALTHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for KINERET® (anakinra) for the treatment of Coronavirus Disease 2019 (COVID-19) in adult patients who are hospitalized with positive results of d
ZacksSwedish Orphan Biovitrum (BIOVF) Beats Q3 Earnings Estimates
Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 16.67% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Sobi to Present Data from REAL-HLH Study at the ACR Convergence 2022 Meeting
Data presented from the REAL-HLH study; the first study of patients treated with Gamifant in a real-world clinical settingWALTHAM, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of the Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI), a specialized international biopharmaceutical company transforming the lives of people with rare diseases, today announced a presentation from the REAL-HLH study – a chart review study which assessed real-world treatm
ZacksAre Medical Stocks Lagging Alimera Sciences (ALIM) This Year?
Here is how Alimera Sciences (ALIM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
- Zacks
Is Swedish Orphan Biovitrum (BIOVF) Stock Outpacing Its Medical Peers This Year?
Here is how Swedish Orphan Biovitrum (BIOVF) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.
ZacksSwedish Orphan Biovitrum (BIOVF)'s Technical Outlook is Bright After Key Golden Cross
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ZacksIs Humana (HUM) Outperforming Other Medical Stocks This Year?
Here is how Humana (HUM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
ZacksHas Swedish Orphan Biovitrum (BIOVF) Outpaced Other Medical Stocks This Year?
Here is how Swedish Orphan Biovitrum (BIOVF) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.
Business WireADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories
LAUSANNE, Switzerland, July 08, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the United States, greater China, Singapore and Japan. The Marketing Authorization Application (MAA) for ZYNLONTA was validated by the European Medicines Agency (EMA) at the end of October 2021, and orphan d
- GlobeNewswire
Sobi Announces Launch of the INTO-HLH Registry, a Disease Registry for Patients with Hemophagocytic Lymphohistiocytosis (HLH)
INTO-HLH Registry serves as the first in-depth disease registry for the HLH medical and patient community in North AmericaWALTHAM, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Sobi® North America today announced the launch of the INTO-HLH Registry, a new disease registry for patients with hemophagocytic lymphohistiocytosis (HLH). The INTO-HLH Registry (Insight into the Natural history and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis) will enroll pediatric and adult patients with HLH, a r
ZacksSwedish Orphan Biovitrum (BIOVF) Stock Jumps 5.3%: Will It Continue to Soar?
Swedish Orphan Biovitrum (BIOVF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
GlobeNewswireApellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for PNH at EHA 2022 Congress
WALTHAM, Mass. and STOCKHOLM, Sweden, June 10, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today reported new analyses of Phase 3 studies that reinforce the robust efficacy and safety profile of EMPAVELI®/Aspaveli® (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH). The data will be presented at the hybrid European Hematology Association (EHA) Congress in Vienna, Austria. New analyses demonstrated that treatment with EMPAVELI resulted in
- GlobeNewswire
Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need
WALTHAM, Mass. and STOCKHOLM, Sweden, June 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced that the first patient has been dosed in the Phase 3 VALIANT study investigating pegcetacoplan, a targeted C3 therapy, in primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G), two rare and debilitating kidney diseases with similar underlying causes and no approved treatment. “Individuals with IC-
